Evidence map›Paper›PMID 36560772›Full record

ArticleViruses2022

Novel 6-Aminoquinazolinone Derivatives as Potential Cross GT1-4 HCV NS5B Inhibitors.

Tamer Nasr, Ahmed M Aboshanab, George Mpekoulis, Antonios Drakopoulos, Niki Vassilaki, Grigoris Zoidis, Khaled A M Abouzid, Wafaa Zaghary

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Tamer NasrDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Ain-Helwan, Cairo 11795, Egypt.
Ahmed M AboshanabDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Ain-Helwan, Cairo 11795, Egypt.ORCID 0000-0003-0334-2834
George MpekoulisMolecular Virology Laboratory, Hellenic Pasteur Institute, 11521 Athens, Greece.
Antonios DrakopoulosDepartment of Chemistry and Molecular Biology, University of Gothenburg, SE-412 96 Gothenburg, Sweden.
Niki VassilakiMolecular Virology Laboratory, Hellenic Pasteur Institute, 11521 Athens, Greece.ORCID 0000-0001-7992-3438
Grigoris ZoidisDepartment of Pharmacy, Division of Pharmaceutical Chemistry, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis Zografou, 15771 Athens, Greece.ORCID 0000-0002-9442-5186
Khaled A M AbouzidDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo 11566, Egypt.ORCID 0000-0001-9851-5624
Wafaa ZagharyDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Ain-Helwan, Cairo 11795, Egypt.
Helwan University · EGPasteur Hellenic Institute · GRAin Shams University · EGCairo University · EGNational and Kapodistrian University of Athens · GRUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic hepatitis C virus (HCV) infections are a worldwide medical problem responsible for diverse types of liver diseases. The NS5B polymerase enzyme has become a very interesting target for the development of anti-HCV drugs owing to its fundamental role in viral replication. Here we report the synthesis of a novel series of 1-substituted phenyl-4(1

Indexed as

Antiviral AgentsEnzyme InhibitorsHepacivirusHepatitis C, ChronicHumansQuinazolinonesStructure-Activity RelationshipViral Nonstructural ProteinsVirus ReplicationAntiviral AgentsEnzyme InhibitorsQuinazolinonesViral Nonstructural Proteins6-AminoquinazolinoneAnti HCVdaclatasvirHepatitis Cmolecular dockingNS5B inhibitors

Identifiers

PMID36560772
PMCPMC9782603
OpenAlexW4311397249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.